TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04744649

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: XELOX or SOX
Description: XELOX: Oxaliplatin+Capecitabine; SOX: Oxaliplatin+S-1~Oxaliplatin: 130mg/m2, iv drip for 2h, d1, q3w;~S-1:40\~60mg Bid, d1\~14, q3w;~Capecitabine: 1000mg/m2 Bid, d1-14, q3w;~Neoadjuvant chemotherapy for 4 cycles, adjuvant chemotherapy for 4 cycles.~Drug: Oxaliplatin Oxaliplatin: 130mg/m2，iv drip for 2h，d1, q3w~Drug: S1 S-1: 40\~60mg Bid，d1\~14, q3w~Drug: Capecitabine Capecitabine: 1000mg/m2 Bid, d1-14, q3w Other Name: XELODA~JS001: 240mg, ivdrip, d1, q3w;~S-1:40\~60mg Bid, d1\~14, q3w;~Capecitabine: 1000mg/m2 Bid, d1-14, q3w;~Neoadjuvant chemotherapy for 4 cycles, adjuvant chemotherapy for 4 cycles.~Drug: JS001 JS001, recombinant humanized anti-PD-1 monoclonal antibody for injection; 240mg ivdrip, d1, q3w.~Other Name: PD-1 antibody~Drug: Oxaliplatin Oxaliplatin: 130mg/m2,iv drip for 2h, d1, q3w~Drug: S1 S-1: 40\~60mg Bid,d1\~14, q3w~Drug: Capecitabine Capecitabine: 1000mg/m2 Bid, d1-14, q3w Other Name: XELODA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JS001+XELOX or SOX
Description: XELOX: Oxaliplatin+Capecitabine; SOX: Oxaliplatin+S-1~JS001: 240mg, ivdrip, d1, q3w;~S-1:40\~60mg Bid, d1\~14, q3w;~Capecitabine: 1000mg/m2 Bid, d1-14, q3w;~Neoadjuvant chemotherapy for 4 cycles, adjuvant chemotherapy for 4 cycles.~Drug: JS001 JS001, recombinant humanized anti-PD-1 monoclonal antibody for injection; 240mg ivdrip, d1, q3w.~Other Name: PD-1 antibody~Drug: Oxaliplatin Oxaliplatin: 130mg/m2,iv drip for 2h, d1, q3w~Drug: S1 S-1: 40\~60mg Bid,d1\~14, q3w~Drug: Capecitabine Capecitabine: 1000mg/m2 Bid, d1-14, q3w Other Name: XELODA

Intervention type: DRUG
Group type: OTHER
Intervention: JS001+XELOX or SOX
Description: XELOX: Oxaliplatin+Capecitabine; SOX: Oxaliplatin+S-1~JS001: 240mg, ivdrip, d1, q3w;~S-1:40\~60mg Bid, d1\~14, q3w;~Capecitabine: 1000mg/m2 Bid, d1-14, q3w;~Neoadjuvant chemotherapy for 4 cycles, adjuvant chemotherapy for 4 cycles.~Drug: JS001 JS001, recombinant humanized anti-PD-1 monoclonal antibody for injection; 240mg ivdrip, d1, q3w.~Other Name: PD-1 antibody~Drug: Oxaliplatin Oxaliplatin: 130mg/m2,iv drip for 2h, d1, q3w~Drug: S1 S-1: 40\~60mg Bid,d1\~14, q3w~Drug: Capecitabine Capecitabine: 1000mg/m2 Bid, d1-14, q3w Other Name: XELODA
Study: NCT06150066

Intervention type: OTHER
Intervention: Recruiting samples
Description: The GCF, plaque, and saliva samples will recruited from participants.
Study: NCT06313606

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary fat positive control
Description: Dietary fat-containing meal plan with a specific supplement that may modify fat metabolism
Study: NCT06150066

Intervention type: OTHER
Intervention: Recruiting samples
Description: The GCF, plaque, and saliva samples will recruited from participants.

Intervention type: OTHER
Intervention: Recruiting samples
Description: The GCF, plaque, and saliva samples will recruited from participants.

Intervention type: OTHER
Intervention: Recruiting samples
Description: The GCF, plaque, and saliva samples will recruited from participants.
Study: NCT05527535

Intervention type: DIAGNOSTIC_TEST
Intervention: Diabetic retinopathy screening by artificial intelligence
Description: Screening diabetic patients' eyes with AI through digital health platform

Intervention type: DIAGNOSTIC_TEST
Intervention: Diabetic retinopathy screening by healthcare personnel
Description: Screening diabetic patients' eyes by conventional method (healthcare personnel)
Study: NCT06234839

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L. reuteri (DSM 17938 and ATCC PTA 5289) in form of oral tablets
Description: Each subject of the experimental group was instructed to dissolve inside the mouth two tablets per day (in the morning and before going to bed at night), during the experimental period of 30 days. The tablets were provided by BioGaia ProDentis® (Stockholm, Sweden). The tablets contained two strains of L. reuteri (DSM-17938 and ATCC PTA 5289), at a dose of 2 x 108 CFU/tablet.
Study: NCT05487001

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dexamethasone group
Description: 1) Arm l (dexamethasone group) Ultrasound-guided femoral nerve block with 1% lidocaine 15 ml after the end of surgery Postoperative femoral nerve patient controlled analgesia~* Total volume 250 ml (0.375% ropivacaine 60 ml + normal saline 188 ml + dexamethasone 10 mg (2 ml))~* Basal rate 4 mL/hr, Bolus volume 2 mL, Lock-out time 15 min

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: sham group
Description: 2) Arm ll (sham group) Ultrasound-guided femoral nerve block with 1% lidocaine 15 ml after the end of surgery Postoperative femoral nerve patient controlled analgesia~* Total volume 250 ml (0.375% ropivacaine 60 ml + normal saline 190 ml~* Basal rate 4 mL/hr, Bolus volume 2 mL, Lock-out time 15 min
Study: NCT04904497

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early Occupational Therapy
Description: Occupational therapists will implement the following activities:~* Polysensory stimulation: external stimulation for increasing the level of alertness. It will be implemented with SAS 2 one session each 24 h.~* Cognitive stimulation: bundle of exercises for activating mental functions, i.e: alertness, visual perception, memory, calculus, problem solving, praxis, language. Patients with SAS 3, 4 and 5. In SAS \<2, 6\> environmental orientation will be considered~* Basic activities of daily living (BADLs): promotion of independence that initially practice hygiene, personal grooming. Patients with SAS 3, 4 and 5~* Motor function Stimulation: exercises to keep the patient's upper extremities active and functional. Patients with SAS with 3,4 and 5. Patients with SAS 1 and 2 will use adaptations to prevent edema and bedsores on vulnerable body areas~* Education: trained family members and health staff about the intervention process
Study: NCT04267198

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intention Treatment for Anomia
Description: Word retrieval treatment for aphasia that engages right hemisphere intention mechanisms using a left-hand circular gesture.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intention Treatment for Anomia
Description: Word retrieval treatment for aphasia that engages right hemisphere intention mechanisms using a left-hand circular gesture.
Study: NCT06577740

Intervention type: OTHER
Group type: OTHER
Intervention: Otago Exercise
Description: Group-based otago exercises were performed for 4 weeks. They were also given a brochure containing otago exercises twice a week and applied individually and followed remotely. They were asked to walk normally for 30 minutes twice a week. They then entered a 4-week washout period.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dual Task Focused Otago Exercise
Description: After a 4-week washout period, face-to-face group-based and dual-task focused otago exercises were applied once a week for 4 weeks. Participants were given a brochure containing otago exercises including dual-task exercises twice a week and applied individually and monitored remotely. They were asked to walk normally for 30 minutes twice a week.
Study: NCT05243797

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teclistamab
Description: Teclistamab will be administered via a subcutaneous injection (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teclistamab
Description: Teclistamab will be administered via a subcutaneous injection (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide will be administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: Lenalidomide will be administered orally
Study: NCT05960773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine/cedazuridine
Description: Decitabine/cedazuridine (INQOVI) oral tablet (35 mg decitabine and 100 mg cedazuridine) taken 3 consecutive days during the first week of every cycle (1 cycle=28-days) for 6 cycles (i.e., 1 course). Additional 6 cycles (i.e., Course 2) for subjects with stable disease or disease regression. Max (total) of 2 treatment courses.
Study: NCT06079359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN1850
Description: Participants will receive a ALXN1850 via subcutaneous (SC) injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo via SC injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo via SC injection.
Study: NCT05776875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab Injection
Description: Atezolizumab is a monoclonal antibody medication used to treat urothelial carcinoma, non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), small cell lung cancer (SCLC), hepatocellular carcinoma, and alveolar soft part sarcoma It is a fully humanized, engineered monoclonal antibody of Immunoglobulin G1 (IgG1) isotype against the protein programmed cell death-ligand 1 (PD-L1).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab, is a medication used to treat a number of types of cancers and a specific eye disease. For cancer, it is given by slow injection into a vein (intravenous) and used for colon cancer, lung cancer, glioblastoma, and renal-cell carcinoma. In many of these diseases it is used as a first-line therapy. For age-related macular degeneration it is given by injection into the eye (intravitreal).

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Transarterial chemoembolization
Description: Transarterial chemoembolization (TACE) is a local therapy for HCC which induces tumor necrosis.
Study: NCT04981002

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Telemedicine Consultation with self orthopedic exam
Description: Brief telemedicine consultation, with self orthopedic exam,blinded to subsequent face-to-face evaluation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Face-to-face Consultation
Description: Direct face-to-face evaluation (without telemedicine consultation before).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Face-to-face Consultation
Description: Direct face-to-face evaluation (without telemedicine consultation before).
Study: NCT06026735

Intervention type: OTHER
Intervention: lung cancer with brain /leptomeningeal metastasis
Description: Cerebrospinal fluid was obtained from the cerebrospinal cavity of non-small cell lung cancer patients with central nervous system metastasis, blood was obtained from veins, and metastatic lung cancer tumor tissue was obtained from surgically resected brain tumors or meningeal tumors. Then comprehensively analyze the exosomes contained in the aforementioned samples, and compare and analyze the clinical data of the patients, so as to explore whether the cancer cell-related substances contained in the cerebrospinal fluid, blood and tumor tissue can be used to predict lung cancer metastasis and Bioindicators of treatment effect.

Intervention type: OTHER
Intervention: lung cancer with brain /leptomeningeal metastasis
Description: Cerebrospinal fluid was obtained from the cerebrospinal cavity of non-small cell lung cancer patients with central nervous system metastasis, blood was obtained from veins, and metastatic lung cancer tumor tissue was obtained from surgically resected brain tumors or meningeal tumors. Then comprehensively analyze the exosomes contained in the aforementioned samples, and compare and analyze the clinical data of the patients, so as to explore whether the cancer cell-related substances contained in the cerebrospinal fluid, blood and tumor tissue can be used to predict lung cancer metastasis and Bioindicators of treatment effect.
Study: NCT06303401

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SI joint thrust manipulation
Description: experimental group given the thrust manipulation along with heating pad. 3 sessions per week will be given for 4 weeks. The pain measure by using NPRS, functional status and disability through ODI will be evaluated.~after every 3 sessions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pelvic stabilization exercises
Description: Heating pad for 10- 15 mints Pelvic stabilization exercises include Bridging (3 sets x 10 reps with 10 secs hold) Pelvic Tilt exercise(3 sets x 10 reps with 10 secs hold) Bird-Dog Exercise (3 sets x 10 reps with 10 secs hold) clamshell Exercise (3 sets x 10 reps with 10 secs hold) .3 sessions per week will be given for 4 weeks. The pain using NPRS , functional status and disability will be evaluated by using ODI after every 3 sessions.
Study: NCT04699474

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Leg ergometer
Description: Leg cycling in bed using motorized ergometer
Study: NCT05032027

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: probiotics
Description: recieving probiotics at the first day of chemoradiotherapy daily
Study: NCT04996914

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Description: 1-2 session TACE before SBRT according to the preference of the interventional radiologist. Goal of TACE is the complete emnbolization of the HCC-nodules. It is allowed to use both conventional TACE (cTACE) and drug-eluting beads TACE (DEB-TACE) according to the interventional radiologist preference.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: SBRT should be 1 month after last TACE. This can be extended till 2 months if indicated. However, prolongation of the gap between TACE and SBRT is not encouraged.~Treatment center should choose one of fractionation schedule mentioned allowed in the study, in order to achieve a balance between dose applied for tumor control and constraints for OAR PTV Dose in 5 / 8 fractions (Gy) BED (α/β 10Gy) 5x 10 Gy @ 83% isodose = 50 Gy (100 Gy) 8 x 7.5 Gy @ 83% isodose = 60 Gy (105 Gy)
Study: NCT05084872

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Patients will be treated by hydroxychloroquine at a dose of 6 to 6.5mg/kg/day during 12 month
Study: NCT05404542

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tavapadon
Description: Oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tavapadon
Description: Oral tablets
Study: NCT05238935

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: prescribed physiotherapy course
Description: provide full assessment and treatment program as postoperative rehabilitation management
Study: NCT06340113

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MCKENZIE AND STABILIZATION EXERCISES
Description: In this group 11 participants will receive McKenzie protocol with stabilization exercises. Participants will be asked to sit to treat extension deficit. The participant will be in a comfortable sitting position with a proper back support. Head is kept in forward facing without any up and done movement (10 to 15 times). Then, he restored the neutral sitting posture, and at the end of the range of motion (ROM), he' tuck in chin by pushing the chin with his fingers (10 to 15 times). The exercises then repeated five or six times in a Session. the session will be of 45 mins, 3 session per week. At end of each session patients will do stabilization exercises with 10reps of each exercise with 10sec hold

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MULLIGAN AND STABILIZATION EXERCISES
Description: . The technique will include Self-sustained Natural Apophyseal Glide (SNAGs), Natural Apophyseal Glides (NAGs), and mobilization techniques.. The participants will receive three sets of Mulligan Mobilization, each set involving 10 repetitions of the exercise, with an interval of 15 to 20 seconds between the sets.At end of each session patients will do stabilization exercises with 10reps of each exercise with 10sec hold.
Study: NCT06222138

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The samples described below will be collected:
Description: For each included patient, blood samples will be collected during baseline visit (before initiation of radio-chemotherapy), then before initiation of TTFields and every 3 months during TTFields treatment. Additional blood samples will be scheduled at recurrence (if applicable).~Moreover, tumor samples (formalin paraffin embedded (FFPE) tumor block and fresh samples) will be collected from surgery specimen on primary tumor by the sponsor for analysis. In case of recurrence, and if a second surgery is possible, tumor samples will also be collected.~Tumor samples will be collected from biopsies taken in the course of routine practice and from surgical specimens collected during surgical procedure.
Study: NCT05344157

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: XSTEM-OA
Description: XSTEM-OA is an allogeneic, adipose tissue-derived, integrin alpha10beta1-selected and expanded mesenchymal stem cell (MSC) product for the treatment of osteoarthritis.
Study: NCT05091580

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpersonal Counseling
Description: Interpersonal Counseling is a brief (4-8 sessions) psychological intervention that was developed to treat depression in primary care. In IPC, counselors provide psychoeducation about the connection of depressive symptoms to social triggers and support patients in leveraging social networks to address these stressors and reduce depressive symptoms. Since depressive symptoms are often a transient reaction to life stress (e.g. TB diagnosis), many individuals are able to achieve significant alleviation of symptoms in as few as four sessions. IPC focuses on reducing interpersonal conflict and improving social cohesion in families, which may have the advantage of strengthening the ability of families to support TB patients in completing treatment to achieve cure. All individuals will be offered 4-5 sessions (weekly), with up to 3 optional booster sessions (monthly) until TB treatment is completed.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Enhanced treatment as usual
Description: Depression screening and referral (as needed)
Study: NCT05944744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adenosylcobalamin
Description: The drug contains Cobamamide / Adenosylcobalamin with dose of 3000 mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The drug doesn't contain any properties or substances for treatment.
Study: NCT05585723

Intervention type: BEHAVIORAL
Intervention: Questionnaires completion
Description: Prospective, qualitative, observational, single-center study. 1) Two independent translations of the original questionnaires into French, 2) Back-translation of the consensus version into English by a professional bilingual translator 3) We will submit this final version to two opinion leaders in France. 4) Evaluation of the clarity, comprehension and acceptability of the translation of the questionnaire.

Intervention type: BEHAVIORAL
Intervention: Questionnaires completion
Description: Prospective, qualitative, observational, single-center study. 1) Two independent translations of the original questionnaires into French, 2) Back-translation of the consensus version into English by a professional bilingual translator 3) We will submit this final version to two opinion leaders in France. 4) Evaluation of the clarity, comprehension and acceptability of the translation of the questionnaire.

Intervention type: BEHAVIORAL
Intervention: Questionnaires completion
Description: Prospective, qualitative, observational, single-center study. 1) Two independent translations of the original questionnaires into French, 2) Back-translation of the consensus version into English by a professional bilingual translator 3) We will submit this final version to two opinion leaders in France. 4) Evaluation of the clarity, comprehension and acceptability of the translation of the questionnaire.
Study: NCT05887193

Intervention type: DEVICE
Intervention: Biothesiometry
Description: Biothesiometry using Biothesiometer (Bio Medical Instrument Co, Ohio, United States of America), placed on glans penis and second finger of nondominant hand.

Intervention type: DEVICE
Intervention: Biothesiometry
Description: Biothesiometry using Biothesiometer (Bio Medical Instrument Co, Ohio, United States of America), placed on glans penis and second finger of nondominant hand.

Intervention type: DEVICE
Intervention: Biothesiometry
Description: Biothesiometry using Biothesiometer (Bio Medical Instrument Co, Ohio, United States of America), placed on glans penis and second finger of nondominant hand.
Study: NCT06343415

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: GAIT-assisted training
Description: GAIT duration starts when walking is started. The participant will walk as intensively as possible within prespecified safety limits. Intensity is considered the most important factor for the feasibility outcome of the completion ratio and for the safety outcomes. Intensity encompasses duration and repetitions.~Duration: 10 minutes is considered the minimum acceptable duration for a session to be deemed complete and 30 minutes as the maximum duration for a training session.~Repetitions: A step intensity of approximately 1000 steps per session is considered as high intensity and training aims to reach this amount. This is based on neuroplasticity theories. Speed starts at 1 km/h and is adjusted accordingly.~The body weight support (BWS) is kept between 60-100% of total body weight. The BWS is adjusted so the knee flexion in the stance phase does not exceed 10 degrees. The guidance force is kept at 100% and symmetric in all sessions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: STEP-assisted training
Description: STEP duration starts when stepping and elevation are started. The participant will step as intensively as possible within prespecified safety limits. Intensity is considered the most important factor for the feasibility outcome of the completion ratio and for the safety outcomes. Intensity encompasses duration and repetitions.~Duration: 10 minutes is considered the minimum acceptable duration for a session to be deemed complete and 30 minutes as the maximum duration for a training session.~Repetitions: A step intensity of approximately 1000 steps per session is considered as high intensity and training aims to reach this amount. This is based on neuroplasticity theories. Step cadence starts at 40 steps/minute and cadence is adjusted accordingly.~The leg loading starts a 5 kg and is, if possible, increased to a maximum of 40% of total body weight while adjusting knee extension to ≤10 degrees flexion in stance. The guidance force is kept at 100% and symmetric in all sessions.
Study: NCT05643742

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CTX112
Description: CTX112 (CD19-directed T-cell immunotherapy comprised of allogeneic T cells genetically modified ex vivo using CRISPR-Cas9 gene editing components)
Study: NCT05560568

Intervention type: OTHER
Intervention: Sleep parameters data collection
Description: Sleep parameters collected before and after hybrid close-loop pump activation. Data collected with adequate devices (i.e. actigraph and Dreem Band).